世界の前立腺がん核医療診断市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5968 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、前立腺がん核医療診断の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（SPECT、PET）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・前立腺がん核医療診断の市場動向 ・企業の競争状況、市場シェア ・前立腺がん核医療診断の種類別市場規模と予測2016-2027（SPECT、PET） ・前立腺がん核医療診断の用途別市場規模と予測2016-2027（病院、クリニック、その他） ・前立腺がん核医療診断の北米市場規模2016-2027（アメリカ、カナダ） ・前立腺がん核医療診断の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・前立腺がん核医療診断のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・前立腺がん核医療診断の中南米市場規模2016-2027（メキシコ、ブラジル） ・前立腺がん核医療診断の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Blue Earth Diagnostics、PETNET Solutions、Cardinal Health、Lantheus Medical Imaging、Jubilant Pharma、NCM-USA、Progenics Pharma、Telix Pharma、ImaginAb、Theragnostics、Novartis、Alliance Medical） ・結論

Nuclear medicine, a type of imaging that uses radioactive materials, is a useful tool to detect and also treat prostate cancer. It is a form of diagnostic imaging that helps radiologists determine the stage of cancer.

Market Analysis and Insights: Global Prostate Cancer Nuclear Medicine Diagnostics Market
The global Prostate Cancer Nuclear Medicine Diagnostics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Prostate Cancer Nuclear Medicine Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Prostate Cancer Nuclear Medicine Diagnostics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Prostate Cancer Nuclear Medicine Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Prostate Cancer Nuclear Medicine Diagnostics market.

Global Prostate Cancer Nuclear Medicine Diagnostics Scope and Market Size
Prostate Cancer Nuclear Medicine Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Prostate Cancer Nuclear Medicine Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
SPECT
PET

Segment by Application
Hospitals
Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Blue Earth Diagnostics
PETNET Solutions
Cardinal Health
Lantheus Medical Imaging
Jubilant Pharma
NCM-USA
Progenics Pharma
Telix Pharma
ImaginAb
Theragnostics
Novartis
Alliance Medical

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 SPECT
1.2.3 PET
1.3 Market by Application
1.3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Perspective (2016-2027)
2.2 Prostate Cancer Nuclear Medicine Diagnostics Growth Trends by Regions
2.2.1 Prostate Cancer Nuclear Medicine Diagnostics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Prostate Cancer Nuclear Medicine Diagnostics Historic Market Share by Regions (2016-2021)
2.2.3 Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Regions (2022-2027)
2.3 Prostate Cancer Nuclear Medicine Diagnostics Industry Dynamic
2.3.1 Prostate Cancer Nuclear Medicine Diagnostics Market Trends
2.3.2 Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
2.3.3 Prostate Cancer Nuclear Medicine Diagnostics Market Challenges
2.3.4 Prostate Cancer Nuclear Medicine Diagnostics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Revenue
3.1.1 Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Revenue (2016-2021)
3.1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Players (2016-2021)
3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Prostate Cancer Nuclear Medicine Diagnostics Revenue
3.4 Global Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Ratio
3.4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prostate Cancer Nuclear Medicine Diagnostics Revenue in 2020
3.5 Prostate Cancer Nuclear Medicine Diagnostics Key Players Head office and Area Served
3.6 Key Players Prostate Cancer Nuclear Medicine Diagnostics Product Solution and Service
3.7 Date of Enter into Prostate Cancer Nuclear Medicine Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Prostate Cancer Nuclear Medicine Diagnostics Breakdown Data by Type
4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size by Type (2016-2021)
4.2 Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Type (2022-2027)

5 Prostate Cancer Nuclear Medicine Diagnostics Breakdown Data by Application
5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size by Application (2016-2021)
5.2 Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size (2016-2027)
6.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type
6.2.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021)
6.2.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027)
6.2.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2027)
6.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application
6.3.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021)
6.3.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027)
6.3.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2027)
6.4 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
6.4.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021)
6.4.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size (2016-2027)
7.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type
7.2.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021)
7.2.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027)
7.2.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2027)
7.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application
7.3.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021)
7.3.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027)
7.3.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2027)
7.4 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
7.4.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021)
7.4.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size (2016-2027)
8.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type
8.2.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2027)
8.3 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application
8.3.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2027)
8.4 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region
8.4.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size (2016-2027)
9.2 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type
9.2.1 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021)
9.2.2 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027)
9.2.3 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2027)
9.3 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application
9.3.1 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021)
9.3.2 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027)
9.3.3 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2027)
9.4 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
9.4.1 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021)
9.4.2 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size (2016-2027)
10.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type
10.2.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2027)
10.3 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application
10.3.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2027)
10.4 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
10.4.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Blue Earth Diagnostics
11.1.1 Blue Earth Diagnostics Company Details
11.1.2 Blue Earth Diagnostics Business Overview
11.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.1.4 Blue Earth Diagnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
11.1.5 Blue Earth Diagnostics Recent Development
11.2 PETNET Solutions
11.2.1 PETNET Solutions Company Details
11.2.2 PETNET Solutions Business Overview
11.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.2.4 PETNET Solutions Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
11.2.5 PETNET Solutions Recent Development
11.3 Cardinal Health
11.3.1 Cardinal Health Company Details
11.3.2 Cardinal Health Business Overview
11.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.3.4 Cardinal Health Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
11.3.5 Cardinal Health Recent Development
11.4 Lantheus Medical Imaging
11.4.1 Lantheus Medical Imaging Company Details
11.4.2 Lantheus Medical Imaging Business Overview
11.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.4.4 Lantheus Medical Imaging Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
11.4.5 Lantheus Medical Imaging Recent Development
11.5 Jubilant Pharma
11.5.1 Jubilant Pharma Company Details
11.5.2 Jubilant Pharma Business Overview
11.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.5.4 Jubilant Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
11.5.5 Jubilant Pharma Recent Development
11.6 NCM-USA
11.6.1 NCM-USA Company Details
11.6.2 NCM-USA Business Overview
11.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.6.4 NCM-USA Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
11.6.5 NCM-USA Recent Development
11.7 Progenics Pharma
11.7.1 Progenics Pharma Company Details
11.7.2 Progenics Pharma Business Overview
11.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.7.4 Progenics Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
11.7.5 Progenics Pharma Recent Development
11.8 Telix Pharma
11.8.1 Telix Pharma Company Details
11.8.2 Telix Pharma Business Overview
11.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.8.4 Telix Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
11.8.5 Telix Pharma Recent Development
11.9 ImaginAb
11.9.1 ImaginAb Company Details
11.9.2 ImaginAb Business Overview
11.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.9.4 ImaginAb Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
11.9.5 ImaginAb Recent Development
11.10 Theragnostics
11.10.1 Theragnostics Company Details
11.10.2 Theragnostics Business Overview
11.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.10.4 Theragnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
11.10.5 Theragnostics Recent Development
11.11 Novartis
11.11.1 Novartis Company Details
11.11.2 Novartis Business Overview
11.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.11.4 Novartis Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
11.11.5 Novartis Recent Development
11.12 Alliance Medical
11.12.1 Alliance Medical Company Details
11.12.2 Alliance Medical Business Overview
11.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Introduction
11.12.4 Alliance Medical Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
11.12.5 Alliance Medical Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of SPECT
Table 3. Key Players of PET
Table 4. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Regions (2016-2021)
Table 8. Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Regions (2022-2027)
Table 10. Prostate Cancer Nuclear Medicine Diagnostics Market Trends
Table 11. Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
Table 12. Prostate Cancer Nuclear Medicine Diagnostics Market Challenges
Table 13. Prostate Cancer Nuclear Medicine Diagnostics Market Restraints
Table 14. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Players (2016-2021)
Table 16. Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Prostate Cancer Nuclear Medicine Diagnostics as of 2020)
Table 17. Ranking of Global Top Prostate Cancer Nuclear Medicine Diagnostics Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Prostate Cancer Nuclear Medicine Diagnostics Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Prostate Cancer Nuclear Medicine Diagnostics Product Solution and Service
Table 21. Date of Enter into Prostate Cancer Nuclear Medicine Diagnostics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type (2016-2021)
Table 25. Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Application (2016-2021)
Table 29. Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 61. Blue Earth Diagnostics Company Details
Table 62. Blue Earth Diagnostics Business Overview
Table 63. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product
Table 64. Blue Earth Diagnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
Table 65. Blue Earth Diagnostics Recent Development
Table 66. PETNET Solutions Company Details
Table 67. PETNET Solutions Business Overview
Table 68. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product
Table 69. PETNET Solutions Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
Table 70. PETNET Solutions Recent Development
Table 71. Cardinal Health Company Details
Table 72. Cardinal Health Business Overview
Table 73. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product
Table 74. Cardinal Health Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
Table 75. Cardinal Health Recent Development
Table 76. Lantheus Medical Imaging Company Details
Table 77. Lantheus Medical Imaging Business Overview
Table 78. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product
Table 79. Lantheus Medical Imaging Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
Table 80. Lantheus Medical Imaging Recent Development
Table 81. Jubilant Pharma Company Details
Table 82. Jubilant Pharma Business Overview
Table 83. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product
Table 84. Jubilant Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
Table 85. Jubilant Pharma Recent Development
Table 86. NCM-USA Company Details
Table 87. NCM-USA Business Overview
Table 88. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product
Table 89. NCM-USA Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
Table 90. NCM-USA Recent Development
Table 91. Progenics Pharma Company Details
Table 92. Progenics Pharma Business Overview
Table 93. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product
Table 94. Progenics Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
Table 95. Progenics Pharma Recent Development
Table 96. Telix Pharma Company Details
Table 97. Telix Pharma Business Overview
Table 98. Telix Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
Table 99. Telix Pharma Recent Development
Table 100. ImaginAb Company Details
Table 101. ImaginAb Business Overview
Table 102. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product
Table 103. ImaginAb Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
Table 104. ImaginAb Recent Development
Table 105. Theragnostics Company Details
Table 106. Theragnostics Business Overview
Table 107. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product
Table 108. Theragnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
Table 109. Theragnostics Recent Development
Table 110. Novartis Company Details
Table 111. Novartis Business Overview
Table 112. Novartis Prostate Cancer Nuclear Medicine Diagnostics Product
Table 113. Novartis Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
Table 114. Novartis Recent Development
Table 115. Alliance Medical Company Details
Table 116. Alliance Medical Business Overview
Table 117. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product
Table 118. Alliance Medical Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021) & (US$ Million)
Table 119. Alliance Medical Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type: 2020 VS 2027
Figure 2. SPECT Features
Figure 3. PET Features
Figure 4. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Others Case Studies
Figure 8. Prostate Cancer Nuclear Medicine Diagnostics Report Years Considered
Figure 9. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Regions: 2020 VS 2027
Figure 12. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Regions (2022-2027)
Figure 13. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Players in 2020
Figure 14. Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Prostate Cancer Nuclear Medicine Diagnostics as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Prostate Cancer Nuclear Medicine Diagnostics Revenue in 2020
Figure 16. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type (2016-2021)
Figure 17. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type (2022-2027)
Figure 18. North America Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type (2016-2027)
Figure 20. North America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application (2016-2027)
Figure 21. North America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Country (2016-2027)
Figure 22. United States Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type (2016-2027)
Figure 26. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application (2016-2027)
Figure 27. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Share by Country (2016-2027)
Figure 28. Germany Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Share by Region (2016-2027)
Figure 38. China Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type (2016-2027)
Figure 46. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application (2016-2027)
Figure 47. Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Share by Country (2016-2027)
Figure 48. Mexico Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Share by Country (2016-2027)
Figure 54. Turkey Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Blue Earth Diagnostics Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
Figure 58. PETNET Solutions Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
Figure 59. Cardinal Health Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
Figure 60. Lantheus Medical Imaging Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
Figure 61. Jubilant Pharma Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
Figure 62. NCM-USA Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
Figure 63. Progenics Pharma Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
Figure 64. Telix Pharma Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
Figure 65. ImaginAb Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
Figure 66. Theragnostics Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
Figure 67. Novartis Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
Figure 68. Alliance Medical Revenue Growth Rate in Prostate Cancer Nuclear Medicine Diagnostics Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---